Our Tests

Arrhythmogenic right ventricular cardiomyopathy panel

Also known as: ARVC, arrhythmogenic right ventricular dysplasia

« Back to test list


Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a familial disorder caused by mutations in any one of a number of genes. There are autosomal dominant and autosomal recessive forms of the disease.

The diagnosis of ARVC is made on the basis of clinical, electrocardiographic, and cardiac imaging findings. Genetic testing is not necessary to make this diagnosis.

This test result has implications regarding the aetiology and inheritance of ARVC in an individual, and the risk of ARVC and related disorders in a patient’s relatives.

This is an assay for heritable mutations. It may raise issues of ethics or consent that are different from most other investigations ordered in the routine care of a patient.

This test can assist in making a diagnosis in an affected patient. It may also provide useful risk information for unaffected relatives. Testing unaffected people to provide risk information may require that the clinician comply with guidelines provided by professional and regulatory authorities regarding pre-test counselling and consent. In particular, national regulations stipulate that carrier testing of an unaffected child requires the laboratory to have evidence of pre-test counselling by a genetics professional and written consent. For advice or assistance, please contact us on 1800 010 447.

Clinical Utility

A pathogenic mutation can be found in approximately 50% of patients with a clinical diagnosis of ARVC.

In an affected person with a clinical diagnosis of ARVC, the presence of a pathogenic mutation confirms the diagnosis and may provide additional information regarding prognosis, mode of inheritance, and the risk of cardiac and non-cardiac manifestations in relatives. However, the absence of a pathogenic mutation in such a patient does not exclude the diagnosis of ARVC.

In an affected person with clinical features suggestive, but not diagnostic, of ARVC, the presence of a pathogenic mutation may be sufficient to confirm the diagnosis.

In an unaffected person from a family with confirmed genetic diagnosis of ARVC, the presence of the family’s mutation may indicate an increased risk of developing ARVC, and close clinical follow-up may be warranted. The interpretation of such results depends on the particular gene, mutations, and mode of inheritance in the family. Pre-test genetic counselling is required.



This test involves analysis a number of genes. Details of this gene panel and potential incidental findings are summarized here.

Test Method

Analysis of a gene panel for sequence abnormalities and deletions/duplications.

This test is provided by Bioscientia, a Sonic Healthcare laboratory in Germany. Bioscientia is accredited within Germany and by the College of American Pathology for the provision of medical genetic tests.

Test Ordering

This test is usually requested by a cardiologist with experience in the genetic management of cardiac disease or a clinical geneticist.

2-5 mL blood in EDTA. Specimens may be collected by the requesting practitioner or at any Sonic Healthcare pathology collection centre.

To help ensure the quality of the test, a genetic test should be done with a dedicated sample whenever possible i.e. a sample collected specifically for that test rather than a sample that is used for multiple tests.

We also recommend that the patient or another adult check the labelling of request forms and sample tubes.

Special Instructions

Please include a statement about family history (or absence of family history) of the disease in clinical details on referral form. If family history is present, please state relationship to patient.



This is the price for initial genetic testing of an affected person. Once a family's mutation is identified, targeted mutation analysis can be offered to family members; please contact Sonic Genetics on 1800 010 447 or at info@sonicgenenetics.com.au regarding price and turn-around time.

Medicare Rebate

This test is not rebated by Medicare. The laboratory assumes that the patient or client has provided informed financial consent for the test.

Turnaround Time

6 weeks

Other Information

Heart Foundation